Muscarinic Effects on Cellular Functions in Cultured Human Ciliary Muscle Cells

Total Page:16

File Type:pdf, Size:1020Kb

Muscarinic Effects on Cellular Functions in Cultured Human Ciliary Muscle Cells Muscarinic Effects on Cellular Functions in Cultured Human Ciliary Muscle Cells Shun Matsumoto, * Thomas Yorio, * Louis DeSantis,] and Iok-Hou Purpose. To characterize the pharmacology of the carbachol-induced changes of phospholi- pase C (PLC) activity and intracellular calcium concentration ([Ca2+]j) in cultured human ciliary muscle cells. Methods. Changes in PLC activity of cultured human ciliary muscle cells were determined by production of inositol phosphates. Single-cell dynamic fluorescence ratio imaging was used to determine [Ca2+];. Results. Carbachol, oxotremorine-M, aceclidine, and pilocarpine stimulated PLC with mean ECsoS of 20, 8, 17, and 2 (JM, respectively. The effect of carbachol on PLC was partially suppressed by extracellular Ca2+ depletion. This muscarinic effect was blocked by muscarinic antagonists, such as atropine (apparent pKj = 9.12, nonselective for muscarinic receptor subtypes), pirenzepine (pKj = 6.76, selective for the Mi receptor subtype), 4DAMP (pKi = 9.25, selective for the M, and M3 subtypes), and fHHSiD (pK< = 7.77, selective for the M3 subtype). In [Ca2+]j experiments, carbachol increased [Ca2+]i transients in human ciliary muscle cells in a dose-dependent manner with a mean EC50 of 7 fjM. 4DAMP was approxi- mately 100 times more potent than pirenzepine in the inhibition of the carbachol-induced [Ca2+]j increase. [Ca2+]j oscillations were observed after carbachol stimulation and persisted after extracellular Ca2+ depletion. Conclusions. Muscarinic agonists activate PLC and increase [Ca2+]i in cultured human ciliary muscle cells through an M3-like muscarinic receptor subtype. Invest Ophthalmol Vis Sci. 1994; 35:3732-3738. L opical application of muscarinic agonists onto the types, named mi to m5, were discovered, mi, m2, and eye lowers intraocular pressure, presumably because m3 correspond to, respectively, the Mb M2, and M3 of the activation of muscarinic acetylcholine receptors subtypes defined by affinity profiles of selective musca- (mAChR), which in turn induce contraction of ciliary rinic antagonists.5 Because both pilocarpine and car- muscles and increase aqueous humor outflow.12 How- bachol are nonselective among the five receptor sub- ever, in addition to their action on aqueous dynamics, types, it is not clear which receptor subtype or subtypes muscarinic agonists, such as carbachol and pilocar- are responsible for the ocular actions of the muscarin- pine, also have ocular side effects. Their common ad- ics. Therefore, it is possible that their ocular hypoten- verse effects include miosis (due to the contraction of sive effects and their side effects are mediated by dif- the iris sphincter muscle), accommodation (change ferent subtypes and, consequently, that appropriate of lens curvature secondary to ciliary muscle contrac- subtype-specific agonists theoretically could lower in- tion), and browache (supposedly due to severe con- traocular pressure with reduced ocular side effects. traction or spasm of the ciliary muscles) .3>4 Indeed, current evidence indicates that one can sepa- Recently, messenger RNAs of five mAChR sub- rate the therapeutic from the untoward effects of the muscarinics. Aceclidine, another muscarinic agonist, is equipotent to pilocarpine in lowering intraocular From the *Department of Pharmacology, North Texas Eye Research Institute, pressure in human subjects, but it is more potent as University of North Texas Health Science Center at Fort Wmth, and ^Glaucoma 6 9 Research, Alcon Laboratories, Fort Wmth, Texas. a miotic and does not cause much accommodation. " Supported in part by a grant from Alcon Laboratories. In monkeys, aceclidine similarly increases the outflow Submitted for publication September 3, 1993; revised February 17, 1994; accepted April 25, 1994. facility of aqueous humor with minimal accommoda- Proprietary interest category: E, C5. tive changes.10 Additionally, the pilocarpine-induced Reprint requests: Shim Matsumoto, M.D., Department of Ophthalmology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunhyo-ku, Tokyo 113, Japan. increase in outflow facility in the monkey can be re- Investigative Ophthalmology & Visual Science, September 1994, Vol. 35, No. 10 3732 Copyright © Association for Research in Vision and Ophthalmology Downloaded from iovs.arvojournals.org on 09/28/2021 Muscarinic Effects on Ciliary Muscle Cells 3733 versed by atropine in two phases, a fast and a slow dium was removed and each well was rinsed with 4X1 phase, whereas the reversal of accommodation shows ml DMEM:nutrient mixture F12 (1:1), supplemented only the fast phase.11 This dissociation of the musca- with 10 mM LiCl (Mallinckrodt, Paris, KY) at room rinic effects agrees with the hypothesis that different temperature. In some experiments, Ca2+ in the me- effects are mediated by different receptor subtypes. dium was chelated with additional ethyleneglycol bis An initial step to test this hypothesis is to identify (2-aminoethylether) tetraacetic acid (EGTA; Sigma, St the receptor subtypes located in the different ocular Louis, MO), forming an EGTA-Ca2+ buffer system (pH tissues. Several published studies attempted to address = 7.4) .20 The cells were incubated with 1 ml of the this issue using receptor binding or techniques of mo- same solution for 10 minutes before 10 (A of agonists lecular biology. In the human iris sphincter, the m3/ were added to the indicated wells. Alternatively, antag- M3 subtype was shown to be the most prominent onists were added at this time and 10 fi\ of carbachol 12 14 mAChR. " The messenger RNA of the m3 receptor (final concentration = 100 /iM) was added 12 minutes was also detected in cultured human ciliary muscle later. After an incubation period of 1 hour, the assay cells and in postmortem tissues.15"17 Recently, based was stopped by the removal of the medium, and 0.5 on results from receptor binding assays, WoldeMussie ml of perchloric acid (Baker, Phillipsburg, NJ) was 12 et al reported that an M3-like mAChR subtype is pres- added. Samples were then incubated on ice for 10 ent in cultured human ciliary muscle cells, and it was minutes. The perchloric acid was later removed by suggested that this receptor may be involved in the extraction with 2 ml of 1:1 (vol/vol) 1,1,2-trichloro- carbachol-induced activation of phosphoinositide me- trifluoro-ethane:tri-n-octylamine (Sigma) mixture. tabolism. Because studies that use ligand binding or The resulting aqueous layer was loaded onto anion- Northern blot analysis can only demonstrate the pres- exchange columns (AG 1-X8 anion exchange resin ence and the cellular concentration of the receptor in formate form, 1 ml; BioRad, Hercules, CA). The protein and the messenger RNA, they do not directly columns were washed with 10 ml of water and 7 ml define the relative importance of the receptor sub- of 50-mM ammonium formate (Sigma). The bound types in cell functions. To expand these studies fur- inositol phosphates were then eluted with 2X2 ml ther, we used cell functional assays (phospholipase C of 1.2 M ammonium formate-0.1 M formic acid activity and intracellular calcium concentration) to try (Sigma). The radioactivity in the eluates was counted to elucidate the functional involvement of muscarinic with a /3-scintillation counter. In recent experiments, receptor subtypes in the cultured human ciliary mus- the assay procedures were simplified such that the cle cells. reaction was terminated by replacing the cell medium with 1 ml of 0.1-M formic acid instead of perchloric acid. The cell lysate was then loaded directly onto the MATERIALS AND METHODS anion-exchange column and eluted, and radioactivity was measured as described. The two assay procedures Cells generated similar results (data not shown). PLC activ- The human ciliary muscle cell strain established by ity of the cells was estimated from the accumulation Tamm et al18 was used. The cells were cultured at of radioactive inositol phosphates. 37°C in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY), supplemented with 10% fetal calf Intracellular [Ca2+] Measurement serum (Hyclone, Logan, UT), 4 mM L-glutamine Human ciliary muscle cells were grown on coverslips (Gibco), and 50 Atg/ml gentamicin (Gibco) in humidi- (#0; Biophysica Technologies, Baltimore, MD) in 6- fied air containing 5% CO2. Upon confluence, the well plates (Costar). The culture medium was changed cells were subcultured by trypsinization using 0.05% to serum-free DMEM 24 hours before the calcium con- trypsin-0.53 mM ethylenediamine-tetraacetic acid centration measurement. On the day of the measure- (Gibco). Cells of passages 10 to 14 were used in subse- ment, the cells were incubated for 60 minutes in a quent experiments. HEPES buffer (125 mM NaCl, 5 mM KC1, 1.8 mM CaCl , 2 mM MgCl , 0.5 mM NaH PO , 5 mM Phospholipase C Assay 2 2 2 4 NaHCO3,10 mM HEPES, 10 mM glucose, 0.1% bovine Phospholipase C activity was assayed according to a serum albumin; pH 7.2) containing 5 fiM of a calcium- procedure modified from that described by Downes fluorescent dye, fura-2 acetoxymethyl ester (Fura-2/ and Michell.19 Human ciliary muscle cells grown in AM; Molecular Probes, Eugene, OR). After the incu- 24-well plates (7 X 105 to 8 X 105 cells per well; Costar, bation, the coverslip was rinsed twice with the same Cambridge, MA) were incubated with myo-[2-3H]-ino- HEPES buffer and mounted in a chamber on the stage sitol (specific activity 370 to 740 GBq/mmol; Amers- of a Nikon Diaphot microscope (Tokyo, Japan). The ham, Arlington Heights, IL) at 5 /t/Ci/ml per well in chamber was filled with 3 ml of the HEPES buffer serum-free Dulbecco's modified Eagle's medium and kept at 37°C during the experiment. Intracellular (DMEM) for 2 days. On the day of the assay, the me- fluorescence intensity of 510-nm emission wavelength, Downloaded from iovs.arvojournals.org on 09/28/2021 3734 Investigative Ophthalmology 8c Visual Science, September 1994, Vol.
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Drug Class Review Ophthalmic Cholinergic Agonists
    Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods .......................................................................................................................................
    [Show full text]
  • Pharmaceuticals
    Tel. +27‐51‐401‐3344 www.liquidtech.co.za FAX +27‐51‐401‐9069 Analysis: Qualitative Package: Pharmaceuticals Aceclidine Bupivacaine Dihydroergotamine Aceprometazine Bupranolol Dilazep Aciclovir Buprenorphine Diltiazem Ajmaline Buspirone Diphenhydramine Aldicarb Sulphone Butaperazine Dipyridamole Aldicarb‐sulfoxide Caffeine Disopyramide alpha‐Hydroxyalprazolam Carazolol Dixyrazine alpha‐Hydroxytriazolam Carbamazepine Doxapram Alprazolam Carbinoxamine Doxepin Alprenolol Carbuterol Ecgoninemethylester Amantadine Carteolol Embutramide Amiloride Carvedilol Enalapril Aminoclonazepam 7‐ Celiprolol Ephedrine Aminoflunitrazepam 7‐ Cetirizine Eprosartan Aminonitrazepam 7‐ Chlorcyclizine Esmolol Aminophenazone Chlordiazepoxide Estazolam Aminopromazine Chlorphenethiazine Ethenzamide Amiodarone Chlorpheniramine Felodipine Amiphenazole Chlorpromazine Fenarimol Amitriptylin Chlorprothixene Fendiline Amoxicillin Cilazapril Fenetylline Amphetamine Cinnarizine Fenfluramine Apomorphine Citalopram Fentanyl Aprinidine Clemastine Fexofenadine Atenolol Clenbuterol Flecainide Atorvastatin Clobazam Fluconazole Atropine Clobutinol Flufenoxuron Aztreonam Clomethiazole Flunitrazepam Befunolol Clomipramine Fluoxetine Bendiacarb Clonazepam Fluphenazine Benzatropine Clonidine Flurazepam Benzocaine Clozapine Fluvoxamine Benzoctamine Cocaine Gabapentin Benzoylecgonine Codeine Gallopamil Berberine Coumatetralyl Glibenclamide Betaxolol Cyclicine Glibornuride Bezafibrate Demeton‐S‐methyl Glimepiride Biperiden Desalkylflurazepam Glipizide Bisoprolol Desipramine Gliquidone
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Aceclidine Hydrochloride (Rinnm) Abates After a Few Days of Continuous Therapy
    Miotics Mydriatics and Antiglaucoma Drugs/Acetazolamide 1875 Aceclidine (USAN, rINN) An oral suspension of acetazolamide 25 mg/mL prepared from 4. Heller I, et al. Significant metabolic acidosis induced by aceta- tablets with the aid of sorbitol solution 70% was stable for at least zolamide: not a rare complication. Arch Intern Med 1985; 145: Aceclidina; Acéclidine; Aceclidinum. 1-Azabicyclo[2.2.2]octan-3- 79 days at 5°, 22°, and 30°. It was recommended that the formu- 1815–17. ol acetate; 3-Quinuclidinol acetate; 3-Acetoxyquinuclidine. 5. Parker WA, Atkinson B. Acetazolamide therapy and acid-base lation be maintained at pH 4 to 5 and stored in amber glass bot- disturbance. Can J Hosp Pharm 1987; 40: 31–4. 2 Ацеклидин tles. 6. Zaidi FH, Kinnear PE. Acetazolamide, alternate carbonic anhy- C9H15NO2 = 169.2. 1. Parasrampuria J, et al. Stability of acetazolamide sodium in 5% drase inhibitors and hypoglycaemic agents: comparing enzymat- CAS — 827-61-2. dextrose or 0.9% sodium chloride injection. Am J Hosp Pharm ic with diuresis induced metabolic acidosis following intraocular ATC — S01EB08. 1987; 44: 358–60. surgery in diabetes. Br J Ophthalmol 2004; 88: 714–15. 7. Chapron DJ, et al. Acetazolamide blood concentrations are ex- ATC Vet — QS01EB08. 2. Alexander KS, et al. Stability of acetazolamide in suspension compounded from tablets. Am J Hosp Pharm 1991; 48: 1241–4. cessive in the elderly: propensity for acidosis and relationship to renal function. J Clin Pharmacol 1989; 29: 348–53. 8. Chapron DJ, et al. Influence of advanced age on the disposition Adverse Effects of acetazolamide.
    [Show full text]
  • Pharmacology
    STATE ESTABLISHMENT «DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE» V.I. MAMCHUR, V.I. OPRYSHKO, А.А. NEFEDOV, A.E. LIEVYKH, E.V.KHOMIAK PHARMACOLOGY WORKBOOK FOR PRACTICAL CLASSES FOR FOREIGN STUDENTS STOMATOLOGY DEPARTMENT DNEPROPETROVSK - 2016 2 UDC: 378.180.6:61:615(075.5) Pharmacology. Workbook for practical classes for foreign stomatology students / V.Y. Mamchur, V.I. Opryshko, A.A. Nefedov. - Dnepropetrovsk, 2016. – 186 p. Reviewed by: N.I. Voloshchuk - MD, Professor of Pharmacology "Vinnitsa N.I. Pirogov National Medical University.‖ L.V. Savchenkova – Doctor of Medicine, Professor, Head of the Department of Clinical Pharmacology, State Establishment ―Lugansk state medical university‖ E.A. Podpletnyaya – Doctor of Pharmacy, Professor, Head of the Department of General and Clinical Pharmacy, State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ Approved and recommended for publication by the CMC of State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ (protocol №3 from 25.12.2012). The educational tutorial contains materials for practical classes and final module control on Pharmacology. The tutorial was prepared to improve self-learning of Pharmacology and optimization of practical classes. It contains questions for self-study for practical classes and final module control, prescription tasks, pharmacological terms that students must know in a particular topic, medical forms of main drugs, multiple choice questions (tests) for self- control, basic and additional references. This tutorial is also a student workbook that provides the entire scope of student’s work during Pharmacology course according to the credit-modular system. The tutorial was drawn up in accordance with the working program on Pharmacology approved by CMC of SE ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ on the basis of the standard program on Pharmacology for stomatology students of III - IV levels of accreditation in the specialties Stomatology – 7.110105, Kiev 2011.
    [Show full text]